Response to chemotherapy of solitary fibrous tumour: A retrospective study

Abstract Background To report on anthracycline-based chemotherapy in a retrospective case-series analysis of solitary fibrous tumour (SFT) patients treated within the Italian Rare Cancer Network. Patients and methods We reviewed a set of SFT treated with chemotherapy since 2002, focusing on anthracy...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2013-07, Vol.49 (10), p.2376-2383
Main Authors: Stacchiotti, S, Libertini, M, Negri, T, Palassini, E, Gronchi, A, Fatigoni, S, Poletti, P, Vincenzi, B, Dei Tos, A.P, Mariani, L, Pilotti, S, Casali, P.G
Format: Article
Language:English
Subjects:
Adult
Aged
Anthracycline
Anthracyclines - administration & dosage
Anthracyclines - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Chemotherapy
Dose-Response Relationship, Drug
Doxorubicin
Female
Haemangioperycitoma
Hematology, Oncology and Palliative Medicine
Humans
Ifosfamide
Ifosfamide - administration & dosage
Kaplan-Meier Estimate
Male
Medical sciences
Middle Aged
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Pharmacology. Drug treatments
Retrospective Studies
Sarcoma
Solitary Fibrous Tumors - drug therapy
Solitary Fibrous Tumors - pathology
Solitary fibrous tumour
Time Factors
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background To report on anthracycline-based chemotherapy in a retrospective case-series analysis of solitary fibrous tumour (SFT) patients treated within the Italian Rare Cancer Network. Patients and methods We reviewed a set of SFT treated with chemotherapy since 2002, focusing on anthracycline, administered alone or in combination with ifosfamide. Responses to ifosfamide as a single agent were also evaluated. Pathologic diagnosis was centrally reviewed, distinguishing typical, malignant (MSFT) and dedifferentiated (DSFT) subtypes. Results Among 42 SFT patients treated with chemotherapy, we selected 31 cases (mean age: 62 years; locally advanced/metastatic: 13/18; front-line/further line: 25/6; typical/MSFT/DSFT/not assessable: 1/17/12/1) who received anthracycline-based chemotherapy (anthracycline monotherapy: eight; anthracycline + ifosfamide: 23). 30 patients are evaluable for response. Best response by Response Evaluation Criteria in Solid Tumours (RECIST) was: partial response (PR): 6 (20%), stable disease (SD): eight (27%), progressive disease (PD): 16 (53%) cases. Responses were confirmed after 3 months. Median progression-free survival (PFS) was 4 (range 2–15) months, with 20% of patients being progression-free at 6 months. PR was found in 2/18 (11%) MSFT and 4/12 (30%) DSFT, with a median PFS of 3.5 and 5 months in MSFT and DSFT, respectively. 19 patients received high-dose prolonged-infusion ifosfamide (front-line/further line: 11/8; typical/MSFT/DSFT: 0/15/4) with two (10%) PR, five (26%) SD, 12 (63%) PD. Conclusions This retrospective series suggests that in SFT anthracyclines have a degree of antitumour activity in the range of soft tissue sarcoma chemotherapy. Ifosfamide monotherapy seemed to have lower activity. A higher response rate was observed in DSFT in comparison to MSFT. Studies on targeted therapies are ongoing.
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2013.03.017